On 14 June 2016 the Dutch competition authority (ACM) approved the acquisition of parts of Mediq by Brocacef subject to remedies following a lengthy Phase II investigation. The activities of the parties overlap in pharmacy retailing and wholesaling to pharmacies and hospitals in the Netherlands. The remedies include the divestment of Mediq’s wholesale activities to hospitals in the Netherlands, and the divestment and termination of franchise and partner contracts with a number of pharmacies to solve (local) overlap concerns. RBB Economics advised Brocacef and its shareholders Phoenix and Celesio throughout the merger control procedure alongside Loyens & Loeff.
Our experience and expertise means our clients have the best chance of success before competition authorities and courts.
We have unrivalled experience across the full range of issues presented by competition law and related associated litigation.
Articles
All Articles- 29/09/2026 Bundeskartellamt unconditionally clears Kemira’s acquisition of Sidra after Phase II review
- 29/09/2026 Bundeskartellamt clears EDEKA’s acquisition of a substantial part of tegut following a Phase II review
- 28/09/2026 Accounting returns and merger assessment in European telecoms – a review of Tarantino et al. (2026)
